The goal of SonALAsense is to turn cancer patients into cancer survivors. SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive way to treat and eradicate deadly cancers like High-Grade Gliomas that typically require debilitating brain surgery that often leads to tumor recurrence.
SonALAsense’s SDT is a non-invasive targeted combination of SONALA-001 (Intravenous Aminolevulinic Acid) and MR-guided focused ultrasound.
SonALAsense is currently recruiting for two trials. The first is SDT-201 Phase 1/2 Clinical Trial for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG). The second is SDT-202 Phase 1/2 Clinical Trial for Adults with Recurrent Glioblastoma (rGBM).
Contact Shreya Prakash